(Q37765584)

22 August 2017

1 reference

title

Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients (English)

1 reference

metastatic renal cell carcinoma

22 August 2017

0 references

1 reference

1 reference

Joaquim Bellmunt

1

1 reference

22 August 2017

Mayer Fishman

series ordinal

2

1 reference

22 August 2017

Timothy Eisen

series ordinal

3

1 reference

22 August 2017

David Quinn

series ordinal

4

1 reference

22 August 2017

1 June 2010

1 reference

Expert Review of Anticancer Therapy

22 August 2017

1 reference

22 August 2017

10

1 reference

22 August 2017

6

1 reference

22 August 2017

825-835

1 reference

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

22 August 2017

1 reference

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

EORTC-GU group expert opinion on metastatic renal cell cancer

21 January 2018

1 reference

The changing pattern of kidney cancer incidence and mortality in Europe

21 January 2018

1 reference

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer

21 January 2018

1 reference

2004 WHO classification of the renal tumors of the adults

21 January 2018

1 reference

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

21 January 2018

1 reference

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Observation should be considered as an alternative in management of renal masses in older and comorbid patients.

21 January 2018

1 reference

Debulking nephrectomy followed by a "watch and wait" approach in metastatic renal cell carcinoma.

21 January 2018

1 reference

21 January 2018

1 reference

Systemic therapy for metastatic renal cell carcinoma.

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer

21 January 2018

1 reference

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

21 January 2018

1 reference

Sequential sorafenib and sunitinib for renal cell carcinoma.

21 January 2018

1 reference

Vascular complications of selected cancer therapies

21 January 2018

1 reference

Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?

21 January 2018

1 reference

History of treated hypertension and diabetes mellitus and risk of renal cell cancer.

21 January 2018

1 reference

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor

21 January 2018

1 reference

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

The screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses.

21 January 2018

1 reference

Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function

21 January 2018

1 reference

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

21 January 2018

1 reference

The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce

21 January 2018

1 reference

Comprehensive geriatric assessment for older patients with cancer

21 January 2018

1 reference

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

21 January 2018

1 reference

Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.

21 January 2018

1 reference

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

Oral anticancer drugs in the elderly: an overview

21 January 2018

1 reference

There's many a slip twixt cup and lip: adherence issues in cancer therapy.

21 January 2018

1 reference

Oral chemotherapy medications: the need for a nurse's touch

21 January 2018

1 reference

Patient adherence and persistence with oral anticancer treatment

21 January 2018

1 reference

Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).

21 January 2018

1 reference

Sorafenib: a promising new targeted therapy for renal cell carcinoma

21 January 2018

1 reference

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.10.68

1 reference

22 August 2017

1 reference